Want to create an interactive transcript for this episode?
Podcast: Fast Five Medtech News Podcast
Episode: Abiomed has a Class I TAVR-related recall, Abbott bets on pipeline to build momentum
Description: Abbott has now seen two quarters in a row of double-digit organic sales growth in its underlying business. Now the company is betting on its productive, innovative pipeline to build momentum. Fast Five hosts Sean Whooley and Danielle Kirsh go over the full performance of the company and how each of its segments performed.
Johnson & Johnson MedTech posted revenues of $7.9 billion, marking a 12.9% improvement year-over-year. Learn what the growth drivers were for the MedTech segment and what analyst's think about the second-quarter results.Â
The initiation of Magnus Medical's neurostim trial marks a significant milestone in the field of mental health t...